NCT00446251View on ClinicalTrials.gov

Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

December 31, 2008

Conditions
Kidney Failure, ChronicDiabetic NephropathiesGlomerulonephritis, IGAHypertension, Renal
Interventions
DRUG

Rituximab

Rituximab dose is 1,000 mg given as an IV infusion every two weeks for 2 doses (days 1 and 15).

DRUG

Mycophenolate mofetil (MMF)

Cellcept is continued from prior study, taken 500 - 1,000 mg BID, P.O.

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Washington

OTHER